Lord, Abbett & Co. LLC Madrigal Pharmaceuticals, Inc. Transaction History

Lord, Abbett & Co. LLC

  • $31.4 Billion
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Oct 07, 2024
BUY
$171.37 - $283.23 $5 Million - $8.27 Million
29,185 Added 42.97%
97,103 $25.9 Million
Q1 2024

May 09, 2024
BUY
$171.37 - $283.23 $16.6 Million - $27.5 Million
97,103 New
97,103 $25.9 Million
Q2 2023

Oct 07, 2024
SELL
$203.88 - $312.0 $21,815 - $33,384
-107 Reduced 0.16%
67,918 $15.7 Million
Q2 2023

Aug 14, 2023
SELL
$203.88 - $312.0 $21,815 - $33,384
-107 Reduced 0.16%
67,918 $15.7 Million
Q1 2023

Oct 07, 2024
SELL
$231.06 - $307.08 $25.5 Million - $33.9 Million
-110,493 Reduced 61.89%
68,025 $16.5 Million
Q1 2023

May 12, 2023
SELL
$231.06 - $307.08 $25.5 Million - $33.9 Million
-110,493 Reduced 61.89%
68,025 $16.5 Million
Q4 2022

Oct 07, 2024
BUY
$58.39 - $296.54 $10.4 Million - $52.9 Million
178,518 New
178,518 $51.8 Million
Q4 2022

Feb 10, 2023
BUY
$58.39 - $296.54 $10.4 Million - $52.9 Million
178,518 New
178,518 $51.8 Million
Q3 2018

Nov 14, 2018
SELL
$207.3 - $300.31 $19.1 Million - $27.7 Million
-92,193 Closed
0 $0
Q2 2018

Aug 14, 2018
BUY
$101.55 - $313.9 $3.25 Million - $10 Million
31,993 Added 53.14%
92,193 $25.8 Million
Q1 2018

May 15, 2018
SELL
$93.35 - $149.04 $3.92 Million - $6.27 Million
-42,042 Reduced 41.12%
60,200 $7.03 Million
Q4 2017

Feb 14, 2018
BUY
$39.35 - $97.37 $4.02 Million - $9.96 Million
102,242
102,242 $9.38 Million

Others Institutions Holding MDGL

# of Institutions
296
Shares Held
21.9M
Call Options Held
819K
Put Options Held
644K
View Full List

About MADRIGAL PHARMACEUTICALS, INC.

MDGL Quotes by TradingView
  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.52B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Lord, Abbett & Co. LLC Portfolio

Follow Lord, Abbett & Co. LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email